Genetics in medicine : official journal of the American College of Medical Genetics · 2026
Not the end of the road: Achieving diagnoses following non-diagnostic exome sequencing: experiences at a clinical site of the Undiagnosed Diseases Network.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Spillmann Rebecca C, Walley Nicole, Schoch Kelly, Mikati Mohamad A, Jobanputra Vaidehi, Shea Patrick, Undiagnosed Diseases Network, Shashi Vandana
Аннотация
PURPOSE: Most participants who undergo exome sequencing (ES) remain undiagnosed. Since clinical ES reanalysis and clinical genome sequencing (GS) provide incremental diagnoses in only 5-15%, better resolution approaches to non-diagnostic ES are needed.
METHODS: Retrospective review of non-diagnostic NGS (ES/GS), at one site of the Undiagnosed Diseases Network (UDN), to assess the diagnostic approaches of ES/GS research reanalysis, clinical GS, non-ES/GS genetic testing and achieving diagnoses from clinical information.
RESULTS: 77/192 (40%) participants with prior non-diagnostic NGS (ES/GS) obtained 80 diagnoses, including known disorders (n=50) and novel gene-disease associations (n=30). Research reanalysis of raw data from prior ES and UDN GS yielded the highest diagnoses (54%), followed by clinical ES/GS (27%), genetic testing other than ES/GS (11%) and clinical diagnoses (8%). Most causal variants were single nucleotide variants (SNVs- 78%) and most were coding (88%). Most (72%) genetic diagnoses should have occurred with prior ES; frequent reasons for diagnoses being overlooked were the prior laboratory not prioritizing: (a) novel gene variants (53%) and, (b) variants in known disorder genes due to perceived phenotypic mismatch (17%).
CONCLUSIONS: An individualized approach to non-diagnostic NGS increased the diagnosis rate beyond reflexive GS. Most subsequent diagnoses and novel gene discoveries were from prioritization of variants amenable to ES.
METHODS: Retrospective review of non-diagnostic NGS (ES/GS), at one site of the Undiagnosed Diseases Network (UDN), to assess the diagnostic approaches of ES/GS research reanalysis, clinical GS, non-ES/GS genetic testing and achieving diagnoses from clinical information.
RESULTS: 77/192 (40%) participants with prior non-diagnostic NGS (ES/GS) obtained 80 diagnoses, including known disorders (n=50) and novel gene-disease associations (n=30). Research reanalysis of raw data from prior ES and UDN GS yielded the highest diagnoses (54%), followed by clinical ES/GS (27%), genetic testing other than ES/GS (11%) and clinical diagnoses (8%). Most causal variants were single nucleotide variants (SNVs- 78%) and most were coding (88%). Most (72%) genetic diagnoses should have occurred with prior ES; frequent reasons for diagnoses being overlooked were the prior laboratory not prioritizing: (a) novel gene variants (53%) and, (b) variants in known disorder genes due to perceived phenotypic mismatch (17%).
CONCLUSIONS: An individualized approach to non-diagnostic NGS increased the diagnosis rate beyond reflexive GS. Most subsequent diagnoses and novel gene discoveries were from prioritization of variants amenable to ES.